The series A funding round was led by Eckert Life Science Accelerator. The financing will help PentixaPharm test PentixaFor and PentixaTher, a pair of radiopharmaceuticals that target the chemokine receptor CXCR4.
The funding will specifically be used for a phase II trial of PentixaFor and a phase I trial of PentixaTher in central nervous system lymphoma. PentixaPharm will also use the funds to support proof-of-concept studies.
Copyright © 2020 AuntMinnieEurope.com